爱游戏平台注册登录
check quantity

AlphaScreen cAMP Detection Kit, 50,000 assay points

AlphaScreen no-wash assay kit for quantitative detection of cAMP.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
6760635D
1,000 assay points
604.00 USD
 
more
6760635M
10,000 assay points
4314.00 USD
 
more
6760635R
50,000 assay points
20800.00 USD
 
more
爱游戏平台注册登录 Life Sciences & Diagnostics is now Revvity, but at this time, there is no change to the supplier information.
Request Technical Support

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

AlphaScreen no-wash assay kit for quantitative detection of cAMP. In this AlphaScreen competition assay, a biotinylated cAMP tracer binds to Streptavidin-coated Donor beads, and interacts with anti-cAMP antibody conjugated to AlphaScreen Acceptor beads. When no cAMP is present, the beads come into close proximity. The excitation of the Donor beads triggers the release of singlet oxygen molecules, which diffuse to the Acceptor beads, resulting in light emission at 520-620 nm. With increasing concentrations of endogenous cAMP, fewer Donor and Acceptor beads are brought together, resulting in a decrease in signal.

 

This kit contains enough reagents to run 1,000 wells using a 25 µL reaction volume. Protocol can be found on the Certificate of Analysis.

 

 

This product replaces 6760625R.

 

Specifications

Assay Target cAMP
Automation Compatible Yes
Product Brand Name AlphaScreen
Quantity in a Package Amount 1.0 per pack
Second Messenger Release cAMP
Shipping Condition Blue Ice
Therapeutic Area Metabolic
Unit Size 50,000 assay points
Resources, Events & More
  • All

Brochure

GPCRs: The Pathway to Discovery

G protein coupled-receptors (GPCRs) are one of the most intensively studied drug targets, with up to one-third of all marketed therapeutics acting by binding to GPCRs. Therapies that target GPCRs include both agonist and antagonists that are used in the treatment of disease in nearly every major ...

PDF 1 MB
Baidu
map